 This is a phase II, single-center study to evaluate the efficacy of a novel cytoreductive regimen followed by CD34E- selected T cell depleted allogeneic stem cell or soybean agglutinated and E-rosetted BM transplant as treatment for patients with acute and chronic leukemias, lymphoma and myelodysplstic syndromePNH. The impact of the change in conditioning regimen and use of CD34-selected T cell depleted PBSCs on transplanted related morbidity and mortality and disease free survival will be assessed. 